Progression of coronary heart disease in cancer patients: the impact of antitumor therapy, as well as the malignant process (literature review)

Results. This analytical review provides a comprehensive assessment of current Russian and international scientific literature focused on the problem of coronary artery disease progression in cancer patients. The literature search was conducted in authoritative domestic and international databases, including PubMed, Scopus, Elsevier, Cochrane Library, Clinical Evidence, Best Evidence, and RSCI, ensuring the representativeness and reliability of the data presented. The relevance of this issue is underscored by a significant increase in the frequency of cardiovascular complications in patients with malignant neoplasms, which is directly linked to both the direct effects of anticancer therapy and the indirect influence of the cancer itself. The review details the key pathogenetic mechanisms contributing to the development and exacerbation of coronary artery disease: Direct cardiotoxicity of anticancer drugs: Particular attention is paid to anthracyclines, which induce oxidative stress and cardiomyocyte apoptosis, leading to myocardial dysfunction. VEGF inhibitors are associated with the development of arterial hypertension and thromboembolic complications, as well as direct damage to the endothelium of coronary arterioles, impairing vasodilatory reserve. HER2-targeted drugs, in turn, can block crucial pathways for cardiomyocyte survival and repair. Systemic effects of the malignant process: Tumor progression is accompanied by chronic systemic inflammation, the release of pro-inflammatory cytokines, and a prothrombotic state, which accelerates atherothrombosis and endothelial dysfunction. Furthermore, the work analyzes epidemiological data on the frequency of coronary artery disease progression and identifies key risk factors in oncology patients, including comorbid conditions (e.g., hypertension, diabetes), cumulative doses of chemotherapeutic agents, the type of targeted therapy received, and the baseline state of the cardiovascular system.
Conclusion. Thus, the conducted analysis confirms that the problem of coronary artery disease progression in cancer patients requires a multidisciplinary approach (onco-cardiology) and the development of strategies for active monitoring, early diagnosis of microvascular dysfunction, and cardioprotection at all stages of anticancer treatment.

1. World health statistics 2021: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization; 2021. Available at: https://apps.who.int/iris/handle/10665/342703. (Аccessed 23.06.2023.)

2. Kazantseva M. L., Oshchepkova E. V., Saidova M. A., Avalyan A. A., Chazova I. F. Long-term cardiovascular complications in oncologic patients after antitumor therapy. Evraziiskii kardiologicheskii zhurnal. 2019; (3): 50-64. https://doi.org/10.38109/2225-1685-2019-3-50-64. (In Russ.)

3. Avalyan A. A., Oshchepkova E. V., Saidova M. A., et al. Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy. Systemic Hypertension. 2018; 15 (4): https://doi.org/10.26442/2075082X.2018.4.000021. (In Russ.)

4. Vasyuk Yu. V., Nesvetov V. V., Shkolnik E. L., Shkolnik L. D., Varlan G. V., Gendlin G. E., et al. Possibilities of ivabradine, a selective inhibitor of ionfchannels of sinus node, in prevention of anthracycline cardiotoxicity in patients with breast cancer. Rational Pharmacotherapy in Cardiology. 2017; 13 (2): 184-190. https://doi.org/10.20996/1819-6446-2017-13-2-184-190. (In Russ.)

5. López-Sendón J., Álvarez-Ortega C., Zamora Auñon P., Buño Soto A., Lyon A. R., Farmakis D., Cardinale D., Canales Albendea M., Feliu Batlle J., Rodríguez Rodríguez I., Rodríguez Fraga O., Albaladejo A., Mediavilla G., González-Juanatey J. R., Martínez Monzonis A., Gómez Prieto P., González-Costello J., Serrano Antolín J. M., Cadenas Chamorro R., López Fernández T. Классификация, распространенность и исходы кардиотоксичности, вызванной противоопухолевой терапией: реестр CARDIOTOX. Eur Heart J. 2020; 41 (18): 1720-1729. DOI: 10.1093/eurheartj/eHaa006. PMID: 32016393.

6. Alekyan B. G., Karapetyan N. G., Gritskevich A. A., Gyoletsyan L. G., Galstyan A. V., Revishvili A. Sh. Cardiac oncology: a modern view on the problem of choosing an optimal strategy for the treatment of coronary artery disease and cancer. Complex Issues of Cardiovascular Diseases. 2023; 12 (3): 98-108. DOI: 10.17802/2306-1278-2023-12-3-98-10. (In Russ.)

7. Potts J. E., Iliescu C. A., Lopez Mattei J. C., Martinez S. C., Holmvang L., Ludman P., De Belder M. A., Kwok C. S., Rashid M., Fischman D. L., Mamas M. A. Percutaneous coronary intervention in cancer patients: A report of the prevalence and outcomes in the United States. European Heart Journal. 2019; 40 (22): 1790-1800. DOI: 10.1093/eurheartj/ehy769.

8. Lyon A. Rr., López-Fernández T., Couch L. S., Asteggiano R., Aznar M. C., Bergler-Klein J., et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal. 2022; 43: 4229-4361. DOI: 10.1093/eurheartj/ehac244.

9. Pearse R. M., Clavien P. A., Demartines N., Fleisher L. A., Grocott M., Haddow J., et al.; International Surgical Outcomes Study group. Global patient outcomes after elective surgery: Prospective cohort study in 27 low-, middle- and high-income countries. Br J Anaesth. 2016; 117 (5): 601-609. DOI: 10.1093/ bja/aew316. Erratum in: Br J Anaesth. 2017; 119 (3): 553.

10. Baquet M., Jochheim D., Mehilli J. Polymer-free drug-eluting stents for coronary artery disease. Journal of Interventional Cardiology. 2018; 31: 330-337. DOI: 10.1111/ joic.12499.

11. Andrushchuk V. V., Polonetski O. L., Ostrovski Yu. P., Kurganovich S. A., Gevorkyan T. T., Kurushko T. V., Krushevskaja T. V. Coronary arteries stenting in patients with tumors of major locations and concomitant coronary heart disease. Cardiology in Belarus. 2020; 12: 483-494. DOI: 10.34883/ PI.2020.12.4.004. (In Russ.)

12. Sardar P., Kundu A., Chatterjee S., Nohria A., Nairooz R., Bangalore S., Mukherjee D., Aronow W. S., Lavie C. J. Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis Clin Cardiol. 2017; 40 (2): 73-81. DOI: 10.1002/clc.22631.

13. Fashafsha Z. Z., Mesitskaya D. F., Kopylov F. Yu., Salpagarova Z. K., Bykova A. A. Diagnostic aspects of cardiovascular complications following chemotherapy. Kardiologiya i serdechno-sosudistaya khirurgiya. 2022; 15 (1): 40-45. DOI: 10.17116/kardio20221501140. (In Russ.)

14. Trontzas I. P., Vathiotis I. A., Kyriakoulis K. G., et al.; ImmunoTTS Collaborative Group. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-S ummary of Included Cases. Cancers (Basel). 2023; 15 (9): 2637. DOI: 10.3390/cancers15092637.

15. Yin J., Yao Z., Pan J., et al. Immune checkpoint inhibitor-related myocarditis in thymic epithelial tumors: Recent progress and perspectives. MedComm-Oncology. 2023; 2 (2): e31. DOI: 10.1002/mog2.31.

16. Vitsenya M. V., Ageev F. T., Gilyarov M. Yu., Ovchinnikov A. G., Orlova R. V., Poltavskaya M. G. Practical recommendations for the correction of cardiovascular toxicity of antitumordrug therapy. Malignant tumors: Practical recommendations of RUSSCO. 2021; 3 (2): 11. (In Russ.)

17. Rubio-Infante N., Ramirez-F lores Y. A., Castillo E. C., et al. A systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety. Front Cell Dev Biol. 2022; 10: 851032. DOI: 10.3389/fcell.2022.851032.

18. Khidirova L. D., Andreeva M. A., Roman G. N. Cardiotoxicity of chemotherapy: current problems and challenges of modern oncology. Kreativnaya kardiologiya. 2024; 18 (Special Issue): S64-S71. DOI: 10.24022/1997-3187-2024-18S-S64-S71. (In Russ.)

19. Gil-Cruz C,. Perez-S hibayama C., De Martin A., et al. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science. 2019; 366 (6467): 881-886. DOI: 10.1126/science.aav3487.

20. Vasyuk Yu. A., Gendlin G. E., Emelina E. I., Nikitin I. G., Potievskaya V. I., Shupenina E. Yu. Guidance letter for cardiologists of oncology institutions on the prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of Cardiology. Cardiovascular Therapy and Prevention. 2023; 22 (7): 3685. doi.org/10.15829/1728-8800-2023-3685. EDN: UOQBUG. (In Russ.)

21. Tan S., Day D., Nicholls S. J., Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review. JACC Cardio Oncol. 2022; 4 (5): 579-597. DOI:10.1016/j.jaccao.2022.09.004. (In Russ.)

22. McDonagh T. A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42 (36): 3599-3726. DOI: 10.1093/eurheartj/ehab368. (In Russ.)

23. Васюк Ю. А., Гендлин Г. Е., Емелина Е. И. и др. Согласованное мнение Российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021; 26 (9): 4703. Vasyuk Yu. A., Gendlin G. E., Emelina E. I., et al. Сonsensus statementof Russian experts on the prevention, diagnosis and treatmentof cardiotoxicity of anticancer therapy. Rossiiskii kardiologicheskii zhurnal. 2021; 26 (9): 4703. DOI: 10.15829/1560-4071-2021-4703. (In Russ.)

24. Khidirova L. D., Latsvieva A. E., Vederin A. V. Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements. Ratsionalnaya farmakoterapiya v kardiologii. 2024; 20 (2): 265-274. https://doi.org/10.20996/1819-6446-2024-3022. EDN: JNMVKN. (In Russ.)

25. Hu J., Tian R., Ma Y., et al. Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and metaanalysis. Front Oncol. 2021; 11: 645245. DOI: 10.3389/fonc.2021.645245. (In Russ.)

26. Suero-Abreu G. A., Zanni M. V., Neilan T. G. Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022; 4 (5): 598615. DOI: 10.1016/j.jaccao.2022.11.011.

27. Lyon A. R., López-Fernández T., Couch L. S., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (ICOS). European Heart Journal. 2022; 43 (41): 4229-4361. DOI: 10.1093/eurheartj/ehac244.

28. Kaprin A. D., Matskeplishvili S. T., Potievskaya V. I., Popovkina O. E., Bolotina L. V., Shklyaeva A. V., Poluektova M. V. Cardiovascular diseases in cancer patients. Onkologiya. Zhurnal im. P. A. Gertsena. 2019; 8 (2): 139-147. https://doi.org/10.17116/onkolog20198021139. (In Russ.)

29. Russian Society of Cardiology. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020; 25 (11): 4083. DOI: 10.15829/1560-4071-2020-4083. (In Russ.)